Publications

Found 383 results
2016
Steichen JM, Kulp DW, Tokatlian T, Escolano A, Dosenovic P, Stanfield RL, McCoy LE, Ozorowski G, Hu X, Kalyuzhniy O et al..  2016.  HIV Vaccine Design to Target Germline Precursors of Glycan-Dependent Broadly Neutralizing Antibodies.. Immunity.
Scheid JF, Horwitz JA, Bar-On Y, Kreider EF, Lu C-L, Lorenzi JCC, Feldmann A, Braunschweig M, Nogueira L, Oliveira T et al..  2016.  HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption.. Nature.
van Gils MJ, van den Kerkhof TLGM, Ozorowski G, Cottrell CA, Sok D, Pauthner M, Pallesen J, de Val N, Yasmeen A, de Taeye SW et al..  2016.  An HIV-1 antibody from an elite neutralizer implicates the fusion peptide as a site of vulnerability.. Nat Microbiol. 2:16199.
Jardine JG, Kulp DW, Havenar-Daughton C, Sarkar A, Briney B, Sok D, Sesterhenn F, Ereño-Orbea J, Kalyuzhniy O, Deresa I et al..  2016.  HIV-1 broadly neutralizing antibody precursor B cells revealed by germline-targeting immunogen.. Science. 351(6280):1458-63.
Chen Y, Wilson R, O'Dell S, Guenaga J, Feng Y, Tran K, Chiang C-I, Arendt HE, DeStefano J, Mascola JR et al..  2016.  An HIV-1 Env-Antibody Complex Focuses Antibody Responses to Conserved Neutralizing Epitopes.. J Immunol. 197(10):3982-3998.
van den Kerkhof TLGM, de Taeye SW, Boeser-Nunnink BD, Burton DR, Kootstra NA, Schuitemaker H, Sanders RW, van Gils MJ.  2016.  HIV-1 escapes from N332-directed antibody neutralization in an elite neutralizer by envelope glycoprotein elongation and introduction of unusual disulfide bonds.. Retrovirology. 13(1):48.
Coss KP, Vasiljevic S, Pritchard LK, Krumm SA, Glaze M, Madzorera S, Moore PL, Crispin M, Doores KJ.  2016.  HIV-1 Glycan Density Drives the Persistence of the Mannose Patch within an Infected Individual.. J Virol. 90(24):11132-11144.
Schoofs T, Klein F, Braunschweig M, Kreider EF, Feldmann A, Nogueira L, Oliveira T, Lorenzi JCC, Parrish EH, Learn GH et al..  2016.  HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1.. Science. 352(6288):997-1001.
Dai K, Khan SN, Wang Y, He L, Guenaga J, Ingale J, Sundling C, O'Dell S, McKee K, Phad G et al..  2016.  HIV-1 Vaccine-elicited Antibodies Reverted to Their Inferred Naive Germline Reveal Associations between Binding Affinity and in vivo Activation.. Sci Rep. 6:20987.
McCoy LE, van Gils MJ, Ozorowski G, Messmer T, Briney B, Voss JE, Kulp DW, Macauley MS, Sok D, Pauthner M et al..  2016.  Holes in the Glycan Shield of the Native HIV Envelope Are a Target of Trimer-Elicited Neutralizing Antibodies.. Cell Rep. 16(9):2327-38.
Gitlin AD, von Boehmer L, Gazumyan A, Shulman, iv Z, Oliveira TY, Nussenzweig MC.  2016.  Independent Roles of Switching and Hypermutation in the Development and Persistence of B Lymphocyte Memory.. Immunity.
Tian M, Cheng C, Chen X, Duan H, Cheng H-L, Dao M, Sheng Z, Kimble M, Wang L, Lin S et al..  2016.  Induction of HIV Neutralizing Antibody Lineages in Mice with Diverse Precursor Repertoires.. Cell. 166(6):1471-1484.e18.
Bornholdt ZA, Turner HL, Murin CD, Li W, Sok D, Souders CA, Piper AE, Goff A, Shamblin JD, Wollen SE et al..  2016.  Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak.. Science. 351(6277):1078-83.
Kong L, Ju B, Chen Y, He L, Ren L, Liu J, Hong K, Su B, Wang Z, Ozorowski G et al..  2016.  Key gp120 Glycans Pose Roadblocks to the Rapid Development of VRC01-Class Antibodies in an HIV-1-Infected Chinese Donor.. Immunity. 44(4):939-50.
Bonsignori M, Zhou T, Sheng Z, Chen L, Gao F, M Joyce G, Ozorowski G, Chuang G-Y, Schramm CA, Wiehe K et al..  2016.  Maturation Pathway from Germline to Broad HIV-1 Neutralizer of a CD4-Mimic Antibody.. Cell.
Krumm SA, Mohammed H, Le KM, Crispin M, Wrin T, Poignard P, Burton DR, Doores KJ.  2016.  Mechanisms of escape from the PGT128 family of anti-HIV broadly neutralizing antibodies.. Retrovirology. 13(1):8.
Jardine JG, Sok D, Julien J-P, Briney B, Sarkar A, Liang C-H, Scherer EA, Dunand CJHenry, Adachi Y, Diwanji D et al..  2016.  Minimally Mutated HIV-1 Broadly Neutralizing Antibodies to Guide Reductionist Vaccine Design.. PLoS Pathog. 12(8):e1005815.
Crispin M, Zeltina A, Zitzmann N, Bowden TA.  2016.  Native functionality and therapeutic targeting of arenaviral glycoproteins.. Curr Opin Virol. 18:70-75.
Moldt B, Le KM, Carnathan DG, Whitney JB, Schultz N, Lewis MG, Borducchi EN, Smith KM, Mackel JJ, Sweat SL et al..  2016.  Neutralizing antibody affords comparable protection against vaginal and rectal simian/human immunodeficiency virus challenge in macaques.. AIDS. 30(10):1543-51.
Stephenson KE, D'Couto HT, Barouch DH.  2016.  New concepts in HIV-1 vaccine development.. Curr Opin Immunol. 41:39-46.
Ackerman ME, Mikhailova A, Brown EP, Dowell KG, Walker BD, Bailey-Kellogg C, Suscovich TJ, Alter G.  2016.  Polyfunctional HIV-Specific Antibody Responses Are Associated with Spontaneous HIV Control.. PLoS Pathog. 12(1):e1005315.
He L, de Val N, Morris CD, Vora N, Thinnes TC, Kong L, Azadnia P, Sok D, Zhou B, Burton DR et al..  2016.  Presenting native-like trimeric HIV-1 antigens with self-assembling nanoparticles.. Nat Commun. 7:12041.
Sok D, Briney B, Jardine JG, Kulp DW, Menis S, Pauthner M, Wood A, Lee E-C, Le KM, Jones M et al..  2016.  Priming HIV-1 broadly neutralizing antibody precursors in human Ig loci transgenic mice.. Science. 353(6307):1557-1560.
Sok D, Pauthner M, Briney B, Lee J H, Saye-Francisco KL, Hsueh J, Ramos A, Le KM, Jones M, Jardine JG et al..  2016.  A Prominent Site of Antibody Vulnerability on HIV Envelope Incorporates a Motif Associated with CCR5 Binding and Its Camouflaging Glycans.. Immunity. 45(1):31-45.
Deruaz M, Moldt B, Le KM, Power KA, Vrbanac VD, Tanno S, Ghebremichael MS, Allen TM, Tager AM, Burton DR et al..  2016.  Protection of Humanized Mice From Repeated Intravaginal HIV Challenge by Passive Immunization: A Model for Studying the Efficacy of Neutralizing Antibodies In Vivo.. J Infect Dis. 214(4):612-6.

Pages